Western University

Scholarship@Western
Bone and Joint Institute
1-1-2017

Delayed Endothelial Progenitor Cell Therapy Promotes Bone
Defect Repair in a Clinically Relevant Rat Model
Brent D. Bates
Li Ka Shing Knowledge Institute

Charles Godbout
Li Ka Shing Knowledge Institute

David J. Ramnaraign
Li Ka Shing Knowledge Institute

Emil H. Schemitsch
London Health Sciences Centre

Aaron Nauth
Li Ka Shing Knowledge Institute

Follow this and additional works at: https://ir.lib.uwo.ca/boneandjointpub
Part of the Medicine and Health Sciences Commons

Citation of this paper:
Bates, Brent D.; Godbout, Charles; Ramnaraign, David J.; Schemitsch, Emil H.; and Nauth, Aaron, "Delayed
Endothelial Progenitor Cell Therapy Promotes Bone Defect Repair in a Clinically Relevant Rat Model"
(2017). Bone and Joint Institute. 1091.
https://ir.lib.uwo.ca/boneandjointpub/1091

Hindawi
Stem Cells International
Volume 2017, Article ID 7923826, 10 pages
https://doi.org/10.1155/2017/7923826

Research Article
Delayed Endothelial Progenitor Cell Therapy Promotes Bone
Defect Repair in a Clinically Relevant Rat Model
Brent D. Bates,1 Charles Godbout,1 David J. Ramnaraign,1 Emil H. Schemitsch,2 and
Aaron Nauth1,3
1

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, University of Toronto, 209 Victoria Street, Toronto,
ON, Canada M5B 1T8
2
Department of Surgery, London Health Sciences Centre, 339 Windermere Road, London, ON, Canada N6A 5A5
3
Department of Surgery, Division of Orthopaedics, St. Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, ON,
Canada M5B 1W8
Correspondence should be addressed to Aaron Nauth; nautha@smh.ca
Received 31 December 2016; Accepted 14 February 2017; Published 30 March 2017
Academic Editor: Gary E. Lyons
Copyright © 2017 Brent D. Bates et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The repair of segmental bone defects remains a signiﬁcant challenge for orthopaedic surgeons. Endothelial progenitor cells (EPCs)
have successfully promoted the repair of acute defects in animal models; however, the ability of EPCs to induce the repair of chronic
nonhealing defects, such as those often encountered clinically, has not been investigated. Therefore, the purpose of this study was to
investigate the ability of EPCs delivered in delayed fashion to induce the repair of nonhealing defects in a clinically relevant model.
In order to simulate delayed treatment, 5 mm segmental defects in Fischer 344 rat femora were treated with bone marrow-derived
EPCs on a Gelfoam scaﬀold at 3 weeks post creation of the defect. At ten weeks posttreatment, 100% of EPC-treated defects
achieved union, whereas complete union was only achieved in 37.5% of defects treated with Gelfoam alone. Furthermore,
signiﬁcant increases in ultimate torque (p = 0 022) and torsional stiﬀness (p = 0 003) were found in EPC-treated defects
compared to controls. Critically, no diﬀerences in outcomes were observed between acute and delayed EPC treatments. These
results suggest that EPCs can enhance bone healing when applied in an acute or delayed fashion and that their use may
represent a clinically translatable therapy for bone healing in humans.

1. Introduction
Despite recent advances in surgical techniques and
implants, the repair of bone defects and nonunion secondary to trauma or infection remains a signiﬁcant challenge.
Fracture nonunion is a debilitating condition that substantially impacts health-related quality of life and creates a
signiﬁcant burden on healthcare systems [1–3]. In the tibia
alone, open fractures develop nonunion in 23% of cases
[3] and demonstrate increasing complication rates as fracture severity and bone defect size increase [4–6]. Autologous
iliac crest bone grafting (AICBG) is the current gold standard
of treatment for bone defects; however, bone grafting is
associated with overall complication rates of 19% [7] and
is further limited by the amount of bone available, donor

site morbidity, and suboptimal healing outcomes [7, 8].
Other treatment modalities including vascularized autografts, cortical allografts, and the Ilizarov technique have
also been utilized for the repair of bone defects [9]. However, similar to AICBG, each of these techniques have
demonstrated high complication rates and substantial limitations in eﬃcacy. A variety of tissue engineering substitutes,
including osteoinductive molecules such as bone morphogenetic proteins (BMPs), osteoconductive scaﬀolds such
as calcium phosphates, and osteoprogenitor cells such as
mesenchymal stem cells (MSCs), have been investigated
as potentially superior treatments for bone defects [10, 11].
However, to date these therapies have failed to translate into
clinical practice. One potentially signiﬁcant limitation of
each of these therapies is their lack of angiogenic capacity
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and failure to address blood supply to the tissue-engineering
construct [12].
Accordingly, angiogenic cell populations, such as EPCs,
have recently been investigated, and our research group
[13–16], as well as others [17–19], has successfully demonstrated the ability of EPCs to aﬀect the repair of segmental
bone defects in animal models when the cells are applied
acutely to freshly created defects. However, the timing of
intervention plays a signiﬁcant role in the eﬃcacy of both
cellular and molecular therapies [20, 21] as a result of the
diﬀering inﬂammatory environments at diﬀerent time
points following trauma. Inﬂammatory cytokines released
immediately after fracture, such as interleukin (IL)-1 and
IL-6 [22, 23], have been shown to stimulate EPC proliferation, migration, adhesion, vascular endothelial growth factor
(VEGF) expression, and tubulogenesis [24–26], suggesting
that local inﬂammation at the fracture site has the potential
to stimulate EPC-mediated repair of acute defects. However,
in the clinical context of open fractures complicated by bone
loss, bone grafting is most commonly delayed to minimize
graft resorption, reduce infection risk, and allow soft tissue
healing at the fracture site [27]. Furthermore, for fractures
that require bone graft treatment for delayed union or nonunion, treatment would typically occur outside of the initial
inﬂammatory window. Therefore, the environment in which
bone grafting or the application of bone graft substitutes
would typically occur in the clinical situation has not been
well replicated in animal models of EPC therapy, which apply
the cells to acutely created bone defects. The current study
sought to address this by investigating EPC therapy in a more
clinically relevant model of delayed treatment.
The primary objective of this study was to investigate the
use of ex vivo expanded EPCs for the regeneration of bone
defects in a clinically relevant model of delayed treatment
using a chronic bone defect. In addition, we sought to compare delayed delivery of EPCs to EPCs delivered in an acute
fashion to evaluate the eﬀects of treatment timing on functional bone repair. We hypothesized that delayed treatment
with ex vivo expanded EPCs surgically transplanted into
chronic bone defects would enhance bone repair in a comparable fashion to acute treatment.

2. Methods
2.1. Experimental Design. Thirty-six male Fischer 344 syngeneic rats weighing 250–300 g underwent open surgery to create a 5 mm segmental defect in the mid-diaphysis of the right
femur, which was then stabilized with a miniplate and
screws. Animals were then randomly assigned to one of ﬁve
groups: (1) delayed EPC group: delayed grafting at 3 weeks
post bone defect creation with Gelfoam scaﬀold (Pﬁzer,
New York City, NY) loaded with 1 × 106 culture-expanded
EPCs in cell culture medium (n = 8); (2) delayed control
group: delayed grafting at 3 weeks post bone defect creation
with Gelfoam control (no cells, soaked in cell culture medium
only) (n = 8); (3) empty defect control group: no additional
treatment at 3 weeks post bone defect creation (n = 8); (4)
acute EPC group: immediate grafting of bone defect with
Gelfoam scaﬀold loaded with 1 × 106 culture-expanded EPCs
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in cell culture medium (n = 6); or (5) acute control group:
immediate grafting with Gelfoam control (no cells, soaked
in cell culture medium only) (n = 6). Animals receiving
immediate treatment were sacriﬁced after 10 weeks. In the
delayed treatment and empty defect control groups, defects
were left empty for the initial 3-week delay, and animals were
sacriﬁced 10 weeks thereafter. All animals were sacriﬁced
by intracardiac injection of T-61 solution while under 2%
isoﬂuorane anaesthetic. In all groups, the operated and nonoperated femora were dissected immediately postsacriﬁce
and then ﬁxed in 10% neutral buﬀered formalin. All protocols were approved by the St. Michael’s Hospital Animal
Care Committee.
2.2. Cell Isolation, Culture, and Characterization. The cell
isolation protocol used in this study was modiﬁed from
our previous protocol [16] and has been published elsewhere [28]. Brieﬂy, bone marrow was ﬂushed from the
medullary canals of rat tibiae and femora with phosphate
buﬀered saline (PBS). Washout solution was collected
and subsequently centrifuged at 360g for 10 minutes at
18°C. The resulting cell pellet was resuspended in endothelial
basal medium (EBM-2) supplemented with EGM-2 MV
SingleQuots™ (Lonza, Walkersville, MD). The cell solution
was transferred to a T-75 ﬂask previously coated with ﬁbronectin (10 mg/mL). Nonadherent cells were removed after
48 h, and the culture was continued for 7-8 days with
medium changes every other day.
Cultured cells were characterized according to their
ability to uptake Ac-LDL and bind UEA-1 lectin. Cells loaded
onto glass coverslips were incubated with 10 μg/mL of Alexa
Fluor® 594 Ac-LDL (Molecular Probes, Eugene, OR) for
4 h at 37°C and 5% CO2. Cells were then ﬁxed with 2%
paraformaldehyde for 10 minutes, incubated with 20 μg/mL
of FITC UEA-1 lectin (Sigma-Aldrich, St. Louis, MO) overnight at 4°C, and subsequently visualized on a ﬂuorescence
microscope (Nikon Eclipse E800, Tokyo, Japan). Additionally, a tube formation assay was used to assess the angiogenic
potential of the cultured cells. Basement membrane Matrigel
(BD Biosciences, Franklin Lakes, NJ) diluted 1 : 2 in EBM2 medium was loaded into a 12-well plate at 300 μL/well
and was allowed to polymerize at 37°C and 5% CO2 for
15 minutes. EPCs were added onto the Matrigel at
25,000 cells/cm2 and were incubated for 24 h at 37°C and
5% CO2. After 24 h, the medium was carefully aspirated,
and Calcein AM diluted in EGM-2 MV medium was
added to each well at 2 μg/mL. Plates were then imaged
at 10× objective using ﬂuorescence microscopy (Zeiss Axio
Observer Live Cell, Oberkochen, Germany). Ten z-stacks
at 10 μm intervals were acquired with ApoTome and shading
correction. Sixteen images in a 4 × 4 layout were captured,
and individual stacks and tiles were stitched together to create a composite 3D image using Imaris software (Bitplane,
Belfast, UK).
2.3. Surgical Procedures. The femoral bone defect surgery has
been previously described in an earlier study [16]. Brieﬂy,
rats were anaesthetized with 2% isoﬂuorane and given
0.05 mg/kg of buprenorphine analgesic preoperatively via
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Table 1: Radiographic scoring system.
Defect ﬁlling
0%
1–25%
26–50%
51–75%
76–100%

Callus density
N/A
Low
High
Low
High
Low
High
Low
High

Score
0
1
2
3
4
5
6
7
8

subcutaneous injection. The right leg was shaved and then
scrubbed with Betadine solution (povidone-iodine, 10%)
and 70% ethanol. All further steps took place under sterile
conditions. Using a lateral approach, an incision was made
in the skin overlying the femur, and the underlying tissue
was dissected to expose the bone surface. Two parallel
osteotomies were created in the middle 1/3 of the femoral
diaphysis using an oscillating saw with 0.9% saline irrigation.
The intervening bone segment was removed, and a 5-hole
mini-plate (Synthes, Mississauga, Canada) was ﬁxed to the
bone with two proximal and two distal 1.5 mm cortical
screws. In the delayed treatment groups, the defect was left
empty and a standardized closure was performed. In the
acute treatment groups, either EPC-loaded Gelfoam or
Gelfoam control was placed in the defect prior to closure.
Rats were allowed full weightbearing and cage activity postoperatively and were given 0.05 mg/kg of buprenorphine
analgesic every 12 hours for the ﬁrst 48 hours postsurgery.
During the secondary surgery for the delayed treatment
groups, anaesthetic and analgesics were given as described
above, and the same surgical approach was utilized to access
the femur. Subsequently, the defect was cleared of ﬁbrous tissue, and the bone ends were debrided with a scalpel to induce
cortical bleeding. A 20-gauge needle was then used to reestablish the medullary canal, which had typically been covered
over by endosteal callus and ﬁbrotic tissue. Then, either EPCloaded Gelfoam or Gelfoam control was placed in the defect
prior to closure.
2.4. Radiographic Assessment. All animals assigned to receive
delayed treatment or no treatment underwent plain radiographic evaluation after the initial 3-week delay. Defects were
scored in a blinded fashion using a radiographic scoring system modiﬁed from Atesok et al. [16] (Table 1), and defects
with scores of 4 or lower were randomized to receive either
EPC-loaded Gelfoam or Gelfoam control or to be left empty
with no further surgical intervention. Defects receiving
scores of 5 or greater were excluded from further study in
order to ensure that the repair of the defect was a result of
the intervention and not spontaneous bone repair.
Postintervention, standardized radiographs were taken
on a biweekly basis to monitor bone repair. Radiographs
taken at the 10-week endpoint were graded using the scoring
system outlined in Table 1. Two blinded orthopaedic surgeons graded all radiographs, and the average scores were

used for analysis. Additionally, defects were characterized
as completely united, incompletely united, or nonunited by
a blinded orthopaedic surgeon.
2.5. MicroCT Analysis. After specimen harvest and plate
removal, the operated femora were placed vertically in a
poly-ethyl-imid (PEI) holder (16.4 mm × 75 mm) ﬁlled with
formalin solution. The samples were scanned at 70 kVp
and 114 μA in high resolution (1000 projections per 180°;
voxel size = 8 μm) on a MicroCT40 system (Scanco Medical, Basserdorf, Switzerland). The integration time of each
projection was 300 ms, and a single scan at each projection
was conducted (frame averaging = 1). Prior to analysis, the
2D transverse (x-z) grayscale images (1206–1344 total
sections) were reconstructed to x-y cross sections (voxel
size = 8 μm; image size = 2048 × 2048 pixels). A rectangular
region of interest (ROI) encapsulating the osteotomy site at
its widest point was drawn on x-y sections, using the margins
of native bone as reference points. For each specimen, the
same ROI was applied across all slices with visible cortex,
creating a 3D rectangular volume of interest (VOI) (mean
volume ± standard error (SE): 72.26 ± 1.430 mm3). Threshold
for morphometric analysis was held constant across all slices
and samples (minimum = 263; maximum = 1000), and the
VOIs were analyzed for quantitative bone morphometry.
Analysis included the following morphometric parameters:
bone volume to total volume fraction (BV/TV (1)), trabecular number (Tb.N∗ (1/mm)), trabecular separation (Tb.Sp∗
(mm)), and trabecular thickness (Tb.Th∗ (mm)).
2.6. Biomechanical Analysis. After microCT analysis, the
femora were taken for biomechanical testing on an MTS
Bionix 858 test system (MTS Systems, Eden Prairie, MN). A
12 in-lb torsional load cell (Futek TFF325, Irvine, CA) was
utilized to ensure optimal testing accuracy. To prepare each
sample, the proximal and distal epiphyseal-metaphyseal
segments of the bones were ﬁrst potted in polymethyl
methacrylate (PMMA) dental cement. The diaphyseal defects
were centred between two potting casings using a 20 mm
gauge length, and the femoral diaphyses were aligned longitudinally to the axis of the machine. The femora were tested
in torsion at a displacement of 1°/second until failure of the
bone or a total displacement of 40°. Ultimate torque and
torsional stiﬀness were used for analysis.
2.7. Statistical Analysis. All statistical analyses were performed on GraphPad Prism version 6.0 (GraphPad Software,
Inc., La Jolla, CA). Analyzed values are expressed as mean ± SE. Data were evaluated using two-way analysis of variance (ANOVA), with Tukey’s honest signiﬁcant diﬀerence
(HSD) multiple comparisons analysis to identify betweengroup diﬀerences. A p value of <0.05 was considered statistically signiﬁcant.

3. Results
3.1. Isolation and Characterization of EPCs. The isolated cell
population displayed spindle-shaped morphology characteristic of EPCs after 7-8 days in culture (Figure 1(a)). Harvested
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Figure 1: Culture and characterization of rat bone marrow-derived EPCs. (a) Cultured cells displayed spindle-shaped morphology
characteristic of EPCs after 7–8 days in culture. (b) EPCs formed tube-like structures after seeding on Matrigel for 24 hours (stained with
Calcein AM). (c) EPCs were characterized by Ac-LDL uptake and UEA-1 lectin binding.

cells were capable of forming tube-like structures when
seeded on Matrigel (Figure 1(b)), and stained double positive
for Ac-LDL uptake and UEA-1 lectin binding (Figure 1(c)).
3.2. Bone Defect Model. At 3 weeks post bone defect creation,
nine animals were excluded from further study as a result of
radiographic scores greater than 4 (mean score: 5.11 ± 0.11).
Twenty-four animals had scores of 4 or lower, and were thus
included for randomization and further study. Prior to repeat
intervention, the mean radiographic score of animals in the
delayed EPC group (2.00 ± 0.33) was not signiﬁcantly diﬀerent from those in the delayed control group (1.75 ± 0.35) or
the empty defect control group (1.50 ± 0.42). Histological
staining of empty defects 3 weeks post bone defect creation
revealed disorganized ﬁbrous tissue and prolapsed muscle
tissue ﬁlling the bone defect and endosteal callus capping
the proximal and distal fracture fragments (data not shown).
The mean endpoint radiographic score for the empty
defect control group was 2.5 ± 0.62, and six of eight (75.0%)

defects went on to radiographic nonunion. The remaining
two defects were considered incompletely united; however,
only one had bridging bone upon microCT and biomechanical analyses.
3.3. Treatment with EPCs Improves Radiographic Healing.
Radiographs of animals from the treatment and control
groups were analyzed. By two-way ANOVA analysis, animals
treated with EPCs had signiﬁcantly greater radiographic
scores at 10 weeks compared to controls (6.89 ± 0.15 versus
4.29 ± 0.67; p < 0 001), whereas no diﬀerence existed between
animals treated in an acute versus delayed fashion. Additionally, all animals receiving EPCs achieved complete
union within 10 weeks of treatment irrespective of the
timing of cell delivery, whereas control animals demonstrated signiﬁcantly lower overall union rates.
In our multiple comparisons analysis, radiographic
scores were not signiﬁcantly diﬀerent between the
delayed EPC and delayed control groups (6.94 ± 0.11 versus
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Figure 2: Treatment of bone defects with EPCs improves radiographic healing. (a) Radiographic scores of rat femoral defects at 10 weeks. The
diﬀerence between EPC treatment and control was statistically signiﬁcant when treatment was applied acutely but not when treatment was
performed in a delayed fashion. No diﬀerence was observed between delayed EPC and acute EPC groups. (b) Representative radiographs
of defects in each group. Complete radiographic union was observed in all animals receiving EPCs, whereas control groups generally
demonstrated incomplete union or nonunion. ∗ denotes signiﬁcant diﬀerence between groups (p < 0 05).
Table 2: Radiographic union rates.

Complete union
Incomplete union
Nonunion

Acute
Control
0%
(0/6)
50%
(3/6)
50%
(3/6)

EPCs
100%
(6/6)
0%
(0/6)
0%
(0/6)

Delayed
Control
EPCs
37.5%
100%
(3/8)
(8/8)
50%
0%
(4/8)
(0/8)
12.5%
0%
(1/8)
(0/8)

EPCs: endothelial progenitor cells.

5.25 ± 0.79; p = 0 212) (Figure 2(a)). However, all eight
(100%) animals in the delayed EPC group achieved complete
union, whereas complete union only occurred in three of
eight (37.5%) animals in the delayed control group
(Table 2). Similarly, all six (100%) animals in the acute EPC
group achieved complete union, whereas complete union
was not observed in any of the animals in the acute control
group. Furthermore, the acute EPC group had signiﬁcantly
higher radiographic scores than the acute control group
(6.83 ± 0.33 versus 3.00 ± 0.97; p = 0 003). Radiographic
scores were not signiﬁcantly diﬀerent between delayed and
acute application of EPCs, nor between delayed and acute
treatment with Gelfoam control. Representative radiographs
from each group are shown in Figure 2(b).
3.4. Treatment with EPCs Enhances Bone Morphometric
Parameters. Quantitative microCT performed 10 weeks postintervention revealed signiﬁcant diﬀerences in bone morphometry between EPC-treated and control groups. By
two-way ANOVA analysis, treatment with EPCs signiﬁcantly
increased bone volume fraction (p < 0 001) and trabecular

number (p < 0 001), and decreased trabecular separation
(p < 0 001) compared to controls (Figure 3). Trabecular
thickness was unchanged between EPC-treated and control
groups. No diﬀerences were observed between animals
treated acutely versus in a delayed fashion.
In our multiple comparisons analysis, bone volume
fraction was unchanged in the delayed EPC group compared
to the delayed control group (p = 0 115) (Figure 4(a)). However, compared to the delayed control group, animals treated
in a delayed fashion with EPCs demonstrated signiﬁcantly
greater trabecular number (p = 0 005) and signiﬁcantly
reduced trabecular separation (p = 0 007). When applied
in an acute fashion, EPCs signiﬁcantly increased bone
volume fraction (p = 0 003), increased trabecular number
(p = 0 010), and decreased trabecular separation (p = 0 005)
compared to control. Trabecular thickness was unchanged
in all groups. Bone morphometric parameters did not diﬀer
between delayed and acute application of EPCs. Figure 4(b)
demonstrates representative 3D reconstructions and x-y
cross sections of bone defects from each group.
3.5. Treatment with EPCs Increases Biomechanical Strength
and Stiﬀness. Biomechanical testing at 10 weeks postintervention revealed signiﬁcant improvements in EPC-treated
versus control animals. By two-way ANOVA analysis, treatment with EPCs signiﬁcantly increased ultimate torque
(149.53 ± 12.51 versus 45.65 ± 20.44; p < 0 001) and torsional
stiﬀness (30.55 ± 1.81 versus 8.34 ± 3.61; p < 0 001) compared
to controls.
In our multiple comparisons analysis, delayed application of EPCs to bone defects signiﬁcantly improved ultimate torque (166.23 ± 14.05 versus 72.14 ± 32.67; p = 0 022)
and torsional stiﬀness (33.01 ± 2.74 versus 14.17 ± 5.56;
p = 0 003) compared to control (Figure 5). Importantly, the
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Figure 3: Treatment with EPCs increases bone formation and
improves bone morphometric parameters. Global comparison
between EPCs and Gelfoam-only controls revealed increased bone
volume fraction, increased trabecular number, and decreased
trabecular separation when treated with EPCs. Trabecular thickness
was unchanged between groups. ∗ denotes signiﬁcant diﬀerence
between groups (p < 0 05).

delayed EPC group demonstrated consistent regeneration of
functional strength and stiﬀness, whereas only four of eight
(50%) animals in the delayed control group had mechanical
stability across the defect. Acute delivery of EPCs resulted
in signiﬁcantly improved ultimate torque (127.26 ± 20.20
versus 10.32 ± 10.32; p = 0 012) and stiﬀness (27.27 ± 1.44
versus 0.56 ± 0.56; p < 0 001) compared to acute delivery of
Gelfoam-only control. No diﬀerences in ultimate torque or
torsional stiﬀness were observed between delayed and acute
treatment with EPCs, nor between delayed and acute treatment with Gelfoam control.

4. Discussion
The reconstruction of bone defects resulting from trauma or
nonunion remains a considerable challenge for orthopaedic
surgeons. While acute treatment with EPCs has proven eﬀective in small animal models, patients presenting with traumatic fractures neither have a readily available source of
EPCs nor have a biological environment at the fracture site
conducive to acute bone reconstruction. In the clinical setting, EPCs would likely be applied during a later secondary
surgery, creating a discrepancy between current models and
potential clinical use. The present study aimed to address this
discrepancy, and our ﬁndings indicate that EPCs delivered
via open surgery to a previously established bone defect are
indeed capable of inducing bone repair. Although the volume
of bone formed upon delayed delivery of EPCs did not diﬀer
signiﬁcantly from the control group, the rate of union and
quality of the bone were far superior when defects were

treated with EPCs. Furthermore, at 10 weeks posttreatment,
defects treated in a delayed fashion with EPCs recovered to
approximately 65% of nonoperated contralateral bone
strength. The mechanical superiority of defects treated
with EPCs may in part be attributed to the more abundant
and more tightly spaced trabeculae in the EPC group;
however, EPCs appeared to contribute signiﬁcantly by
enhancing the rate and quality of defect union. Thus,
EPCs administered to nonhealing bone defects evidently
enhanced bone healing when compared to control treatment, and therefore, EPCs could be a clinically translatable
therapy aimed at the reconstruction of osseous defects in a
delayed fashion.
As part of our objective, we aimed to evaluate the inﬂuence
of timing of EPC application on defect repair. Comparison
between acute and delayed EPC treatment demonstrated no
signiﬁcant diﬀerences in bone repair between the groups, suggesting that treatment with EPCs at either an acute or delayed
stage is eﬀective for the repair of bone defects. These ﬁndings
are inconsistent with previous investigations of delayed defect
reconstruction using cellular and molecular therapies, as
delayed treatment has been unable to induce healing responses
equivalent to those observed with acute treatment [20, 21].
These diﬀerences may be explained by our secondary surgical
procedure in which we elevated the soft tissue envelope and
reestablished the medullary canal in a comparable fashion to
that used clinically in exchange nailing procedures. While
exchange nailing stimulates bone union by replacing a smaller
unreamed nail with a larger reamed nail to enhance the stability at the fracture site, reaming the medullary canal for placement of the nail stimulates periosteal circulation and likely
promotes novel angiogenic stimuli capable of enhancing bone
repair [29]. Similarly, in the model used in the current study,
elevation of the soft-tissue envelope and opening of the medullary canal may promote suﬃcient circulation and angiogenic
stimuli to induce a healing response in combination with
EPCs. Thus, the ability of EPCs to induce adequate bone repair
when treated either immediately after fracture or at a delayed
time point demonstrates the potential clinical utility of EPCs
in bone defect reconstruction.
The mechanisms of EPC-induced bone repair remain
incompletely understood. However, it is well established
that a complex, coordinated coupling of angiogenesis and
osteogenesis is essential to bone regeneration. In normal
healing fractures, BMP-2 and BMP-7 are upregulated at 1
and 14–21 days postfracture, namely, the acute inﬂammatory
stage and the stage of endochondral ossiﬁcation [23]. Conversely, these BMPs are downregulated in models of atrophic
nonunion compared to standard healing controls [30, 31].
Increased VEGF expression after EPC application may
help to stimulate BMP-2 expression in local endothelial cells
[13, 14, 32]. Synergistically, BMP-2 also stimulates VEGF
expression in osteoblasts, further suggesting the coupling
of angiogenesis and osteogenesis [33]. Thus, EPC-induced
expression of VEGF and BMP-2 [13, 14], even after signiﬁcant delay, may help to overcome the deﬁcient signalling
present in fracture nonunion and may initiate the inﬂammatory and endochondral phases of bone repair through
regulation of angiogenesis and osteogenesis. Alternatively,
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Figure 4: Treatment of bone defects with EPCs enhances bone morphometric parameters. (a) Graphical representation of quantitative
microCT parameters. When applied in a delayed fashion, EPCs increased trabecular number and decreased trabecular separation
compared to control. When applied acutely, EPCs increased bone volume fraction and trabecular number, and decreased trabecular
separation. No diﬀerences in any parameter were observed between acute and delayed delivery of EPCs. (b) 3D reconstructions and x-y
cross sections of representative defects from each group (BV/TV nearest the group mean). Treatment with EPCs, either in an acute or
delayed fashion, demonstrated complete defect bridging at 10 weeks postintervention, whereas incomplete union or nonunion was
generally observed in the control groups. ∗ denotes signiﬁcant diﬀerence between groups (p < 0 05).

the secondary surgical procedure is likely to cause an inﬂammatory reaction, which may stimulate EPC activity via IL-1
and IL-6 signalling [24–26]. Still, further investigation into
the molecular pathways involved in EPC-mediated bone
repair is required, and identiﬁcation of these mechanisms
and their interaction with inﬂammatory processes may aid
in tailoring EPC treatments for clinical use.

The limitations of this study include the investigation of a
single delayed time point, and the spontaneous union
observed in a small subset of animals. First, the 3-week delay
used in this study was chosen based on the accelerated biology observed in rodent fracture repair in comparison to
humans [34]. Bone grafting immediately after open fracture
is not performed clinically due to risks of infection and graft
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5. Conclusion
Our results indicate that EPCs are capable of enhancing
radiographic and morphometric bone repair when applied
3 weeks after bony injury, and promote greater and more
consistent recovery of biomechanical function compared
to a control group. Importantly, the healing response
observed upon delayed surgical treatment did not diﬀer
from that of acute treatment. These data suggest that open
surgical delivery of EPCs on a collagen carrier may be
eﬀective when used in a delayed fashion for the treatment
of nonhealing bone defects in a clinically relevant scenario.
Based on the results from this study, EPC-based therapy
could represent a substantial advance for the treatment
of nonunions and traumatic bone defects in humans, and
further research aimed at bringing this novel therapy to
the clinical realm is warranted.

Conflicts of Interest

0
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Delayed

Control
EPCs

Figure 5: Treatment of bone defects with EPCs increases
biomechanical strength and stiﬀness. Torsional testing revealed that
EPC treatment, either in an acute or delayed fashion, increased
ultimate torque and torsional stiﬀness compared to the respective
control groups. For both ultimate torque and torsional stiﬀness, no
diﬀerences were observed between acute and delayed treatment with
EPCs. ∗ denotes signiﬁcant diﬀerence between groups (p < 0 05).

resorption resulting from the inﬂammatory reaction [27, 35].
Instead, delayed bone grafting is normally performed once
the soft tissue envelope has adequately healed and inﬂammation has subsided, often between 6 and 8 weeks postinjury
[35]. In comparison to high-energy open fractures in human
long bones, the rat model utilized in this study achieves soft
tissue closure relatively early after the operation because minimal iatrogenic damage occurs during the fracture surgery.
Three weeks postfracture, inﬂammation has signiﬁcantly
decreased [22, 23], re-epithelialization has occurred, and
based on histological evidence not included in this study,
the defect has been ﬁlled with ﬁbrous tissue. All of these factors considered, we concluded that a 3-week delay in our rat
model suﬃciently replicated the clinical scenario. Still, further investigation with later time points would strengthen
the applicability of this study. Second, it could be argued that
the regeneration of bone was a result of spontaneous union
and not the administration of EPCs. However, animals were
only subjected to randomization if their radiographic score at
3 weeks was 4 or lower, so as to include only animals with
nonhealing defects. Additionally, we conﬁrmed the nonhealing nature of the bone defects in the study by including a
group of animals in which the defect was left empty with
no secondary intervention. The failure of defect bridging in
this group provides suﬃcient evidence to conclude that
bony regeneration in the treatment groups was indeed a
result of secondary surgical intervention and not natural
bone repair.
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